Nuveen
DSGN icon

Nuveen’s Design Therapeutics DSGN Stock Holding History

Nuveen’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.52M Sell
104,734
-22,081
-17% -$275K ﹤0.01% 2725
2026
Q1 		$1.35M Buy
126,815
+1,555
+1% +$15.7K ﹤0.01% 2433
2025
Q4 		$1.17M Sell
125,260
-7,768
-6% -$60.8K ﹤0.01% 2549
2025
Q3 		$1M Hold
133,028
– – ﹤0.01% 2627
2025
Q2 		$448K Sell
133,028
-14,200
-10% -$53.1K ﹤0.01% 2925
2025
Q1 		$568K Sell
147,228
-10,776
-7% -$51.4K ﹤0.01% 2863
2024
Q4 		$975K Sell
158,004
-54,550
-26% -$316K ﹤0.01% 2724
2024
Q3 		$1.14M Hold
212,554
– – ﹤0.01% 2697
2024
Q2 		$712K Buy
212,554
+54,550
+35% +$213K ﹤0.01% 2863
2024
Q1 		$637K Hold
158,004
– – ﹤0.01% 2888
2023
Q4 		$419K Buy
158,004
+4,617
+3% +$10.6K ﹤0.01% 3063
2023
Q3 		$362K Sell
153,387
-1,152
-0.7% -$5.37K ﹤0.01% 2932
2023
Q2 		$974K Buy
154,539
+38,739
+33% +$237K ﹤0.01% 2674
2023
Q1 		$668K Buy
115,800
+21,728
+23% +$163K ﹤0.01% 2737
2022
Q4 		$965K Sell
94,072
-16,062
-15% -$218K ﹤0.01% 2694
2022
Q3 		$1.84M Sell
110,134
-1,327
-1% -$26.4K ﹤0.01% 2439
2022
Q2 		$1.56M Buy
111,461
+32,383
+41% +$437K ﹤0.01% 2566
2022
Q1 		$1.47M Buy
79,078
+5,965
+8% +$91.4K ﹤0.01% 2657
2021
Q4 		$1.32M Buy
73,113
+30,068
+70% +$516K ﹤0.01% 2750
2021
Q3 		$696K Sell
43,045
-468
-1% -$7.78K ﹤0.01% 3104
2021
Q2 		$865K Buy
+43,513
New +$1.1M ﹤0.01% 3055

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Nuveen's DSGN Position: Q2 2026 in Review

Nuveen reduced its Design Therapeutics (DSGN) stake by 17% in Q2 2026, selling an estimated $275K and leaving 104,734 shares worth $1.52M. The position accounts for ﹤0.01% of the portfolio, ranked #2725.

Nuveen first reported a position in DSGN in Q2 2021 and has held it in 21 quarters since. The position peaked at $1.84M in Q3 2022. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Nuveen held 104,734 shares of Design Therapeutics worth $1.52M as of Q2 2026.
  • Nuveen sold 22,081 Design Therapeutics shares in Q2 2026, an estimated $275K.
  • Design Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2725 holding.
  • Nuveen first reported a position in Design Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • Nuveen's Design Therapeutics position peaked at $1.84M in Q3 2022.
  • 136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.